Johnson & Johnson Considering Sale of DePuy Synthes to Apollo for $20 Billion
Johnson & Johnson is reportedly in advanced talks with private equity firm Apollo Global Management to sell its orthopedics unit, DePuy Synthes, for nearly $20 billion. The deal could finalize within weeks but remains subject to potential changes or competing bids. DePuy Synthes generated $9.3 billion in sales last year and is considered the largest global player in orthopedic devices if spun off independently. J&J has also explored spinning off DePuy Synthes as a publicly traded company, aiming to focus on higher-growth segments within its business portfolio. The MedTech unit reported $8.93 billion in quarterly sales for Q2 2026, up slightly from the previous year. This potential sale would be J&J's second major divestiture following the separation of its consumer-health division into Kenvue last year.
Topics: Apollo Global Management DePuy Synthes Johnson & Johnson Orthopedics Unit